通过噬菌体载体筛选胶质瘤细胞结合的内化短肽

目的:寻找与神经胶质细胞瘤细胞系SWO－38特异性结合并内化的短肽序列。方法:利用噬菌体随机12肽库对肿瘤细胞进行5轮全细胞筛选,并分析筛选后单克隆对肿瘤细胞的特异性结合能力。提取单克隆DNA,测序,推导出短肽序列。结果:5轮筛选后的噬菌体库及所挑选13个单克隆中有10个对胶质瘤细胞有特异性的结合,并测序得到两条重复性高的多肽序列。结论:通过噬菌体随机肽库对肿瘤细胞进行全细胞筛选得到的噬菌体多肽能高特异性与肿瘤细胞结合,可作为肿瘤导向药物研究的载体。     

利用噬菌体肽库筛选与人CD59特异性结合的短肽

目的:筛选并鉴定与人CD59分子特异结合的短肽,为设计具有拮抗CD59肿瘤逃逸活性的短肽封条奠定基础。方法:以高表达人CD59的中国仓鼠卵巢细胞(CHO)为靶细胞,采用竞争结合试验,对噬菌体随机12肽库进行5轮亲和筛选。用ELISA筛选噬菌体阳性克隆并对其进行DNA序列分析。结果:随机挑选的16个克隆中,有8个与人CD59的结合力高。测序后,得到3个高度同源的氨基酸序列。DNAstar分析显示,3个序列均与已公布的(PubMed)人CD2的氨基酸序列有一定的同源性。结论:获得的序列H×A××××××P××为设计肿瘤逃逸相关的CD59活性位点的短肽封条提供了技术基础。     

从噬菌体随机肽库筛选CD137结合肽

目的应用噬菌体随机七肽库筛选与人CD137特异结合的肽序列。方法以重组人CD137作为筛选分子，对噬菌体展示随机七肽库进行亲和淘选。经过5轮淘选后，共随机挑选23个噬菌斑并对其进行了扩增和测序，据此推导随机多肽的氨基酸序列。经夹心ELISA进一步鉴定噬菌体克隆与CD137的结合力。^3H-TdR法检测了噬菌体展示多肽对抗CD137Ab刺激的人外周血淋巴细胞增殖反应影响。结果5轮淘选所得的噬菌体回收率逐步提高，显示淘选过程对随机肽库有一定的富集效果。通过对阳性克隆的测序和序列比较分析，得到RPTQGAF、RPTQVAL、RPTQVAF的相似序列和与CD137L具有同源SRS序列的SRSRVRY、HRRPSRS肽序列，ELISA结果显示这5个克隆都有良好的与CD137的结合力。RPTQGAF、RPTQVAL、RPTQVAF和SRSRVRY4个噬菌体展示肽均能在体外抑制抗CD137Ab刺激的淋巴细胞增殖反应。结论通过对噬菌体随机肽库的淘选，得到与CD137结合的相关多肽，为进一步研究CD137与配体结合的特异性位点及其拮抗性多肽药物设计提供了实验依据和结构基础。     

利用体内噬菌体展示技术筛选及鉴定肺癌特异性结合肽

目的利用体内噬菌体展示技术筛选并鉴定与肺癌特异性结合的多肽。方法用肺癌细胞A549接种裸鼠复制荷瘤动物模型,将随机肽库尾静脉注入裸鼠体内,循环15 min后取肿瘤组织中结合的噬菌体,如此进行3轮体内筛选后挑取噬菌体克隆,ELISA初步鉴定噬菌体克隆对肺癌细胞的亲和力、特异性。将阳性噬菌体克隆扩增、测序获得外源多肽氨基酸序列,化学方法合成多肽,鉴定多肽对肺癌细胞和组织的亲和力、特异性。结果ELISA结果显示,随机挑选的20个噬菌体单克隆中,1个对A549具有很强亲和力。测序获得多肽,命名为zp2。化学合成多肽zp2。竞争抑制、细胞免疫荧光和组织免疫荧光实验结果表明多肽zp2与肺癌细胞A549及肺癌组织特异性结合。结论利用体内噬菌体展示技术筛选出与肺癌细胞A549特异性结合的多肽,为肺癌诊断及治疗药物的研制奠定基础。     

P-糖蛋白结合肽的筛选及合成肽鉴定

目的 筛选人膀胱癌P-糖蛋白特异性结合肽并合成鉴定.方法 利用表达获得的P-糖蛋白胞外段融合蛋白为靶蛋白,采用酶联板法筛选噬菌体随机12肽库,化学合成该特异性肽序列,免疫细胞化学方法进行鉴定.结果 从噬菌体随机肽库中筛选获得了与P-糖蛋白特异性结合的噬菌体阳性克隆,测序获得特异性结合肽序列.免疫细胞化学结果显示特异性合成肽可与耐药细胞BIU-87/ADM结合,而与敏感细胞BIU-87不结合.结论 筛选获得的结合肽具有一定的亲和力,可与特定的肿瘤细胞结合,表现出一定的肿瘤特异性;P-糖蛋白结合肽的筛选,为人膀胱癌多药耐药的靶向治疗结论提供实验依据.     

利用体内噬菌体展示技术筛选膀胱癌特异性结合肽

目的:利用体内噬菌体展示技术筛选与人膀胱移行细胞癌特异性结合的小分子多肽。方法:将人膀胱移行细胞癌细胞BIU87接种于裸鼠体内,制备膀胱癌荷瘤小鼠模型,尾静脉注射噬菌体展示环七肽库,然后筛选与膀胱移行细胞癌特异性结合的含外源多肽的噬菌体,经过3轮体内筛选后,免疫组织化学法及ELISA法鉴定单克隆噬菌体对BIU87的亲和力。提取阳性单克隆噬菌体单链DNA进行测序,并推导出外源多肽氨基酸序列,化学合成多肽、制备分子探针后采用激光扫描共聚焦显微镜术及流式细胞术鉴定多肽对膀胱癌细胞和组织的特异性。结果:3轮体内筛选后,噬菌体富集率达到4.334×102倍。免疫组化结果显示,肿瘤组织中噬菌体肽的含量随着每一轮筛选呈增长趋势,且结合逐渐增强,同时由于噬菌体经肝、肾代谢,可见肝脏结合大量非特异性的噬菌体。ELISA结果显示,随机挑选的30个单克隆噬菌体斑中,有24个阳性噬菌体,其中10个噬菌体对BIU87有较强的亲和力,对其测序并推导出3种多肽序列,重复率最高的序列CSSPIGRHC(8/10)命名为NYZL1。化学合成FITC-C6-NYZL1,通过激光扫描共聚焦显微镜术、流式细胞术均证明多肽NYZL1可以特异性结合膀胱癌细胞。结论:利用体内噬菌体展示技术筛选出了与人膀胱移行细胞癌特异性结合的小分子多肽NYZL1,为膀胱癌早期诊断和靶向治疗提供一定的理论依据。     

模拟HIV-1 gp41 CHR表位短肽的筛选及研究

目的 利用针对HIV-1跨膜蛋白gp41CHR序列合成肽C34的单克隆抗体1G1筛选噬菌体12肽库，旨在找寻模拟C34肽表位的序列，同时探索该短肽成为HIV-1gp41NHR与CHR结合抑制物的可能性。方法 以1G1为钓饵蛋白对噬菌体12肽库进行亲和筛选，以双夹心ELISA鉴定阳性克隆。结果 经3轮筛选后，随机挑选17个噬菌体克隆，其中6个克隆与1G1显示出较强的结合活性，上述6个阳性克隆经DNA测序，氨基酸序列相同；HYEFWAWNWEAN，其明显的疏水性质类似于G34N末端，特异性鉴定显示这些克隆均能够与HIV-1gp41N多肽结合，结论 该噬菌体克隆展示肽可模拟HIV-1gp41CHR多肽表位，并可与N多肽结合。     

噬菌体肽库与NCI-H1299细胞筛选肺癌特异性结合多肽ZS-9的初步研究

目的：利用噬菌体肽库与肺癌NCI-H1299细胞筛选出肺癌特异性结合的多肽,研究其亲和力和特异性。方法：以肺癌细胞NCI-H1299为靶细胞,肺二倍体成纤维细胞MRC-5为吸附细胞,与噬菌体随机十二肽库进行三轮筛选,挑取单克隆扩增并测序,进行生物信息学分析、比对;利用ELISA、细胞免疫化学、组织免疫化学方法测定多肽的亲和力和特异性。结果：经过三轮减性筛选发现,随机挑选的9个单克隆中,其中1个对〖JP〗NCI-H1299和A549均具有较高亲和力,将其命名为ZS-9,测序结果为CAT AAT AAG CAT CTT CCG TCT ACG CAG CCT CTT GCG,根据测序结果推导出ZS-9的氨基酸序列HNKHLPSTQPLA,生物信息学分析表明ZS-9的氨基酸序列与美国国立生物技术信息中心(NCBI) GenBank DNA序列数据库和Swiss-Prot蛋白数据库中的已知基因和蛋白无同源性,表明我们筛选到一种新的肺癌相关抗原的配体。结论：利用噬菌体随机十二肽成功筛选出与肺癌细胞NCI-H1299和A549具有较高亲和力的多肽ZS-9,为肺癌的早期诊断和靶向治疗奠定基础。     

EB病毒潜伏膜蛋白1羧基端活化区域2蛋白特异性结合短肽的筛选

目的 利用噬菌体12肽库筛选能与EB病毒潜伏膜蛋白1(LMPl)羧基端活化区域(CTAR)2蛋白特异性结合的短肽.方法 用纯化的CTAR2蛋白筛选噬菌体12肽库.通过夹心ELISA方法分析噬菌体克隆与CTAR2蛋白的亲和力.利用硝酸纤维膜斑点印迹法进行阳性克隆鉴定,并对阳性克隆进行测序及序列分析.结果 CTAR2蛋白对噬菌体12肽库进行3轮筛选,第3轮的产率是第1轮的143倍[(3.0×10-6)/(2.1×10-8)],噬菌体克隆得到较好的富集.ELISA方法提示筛选出来的噬菌体克隆能与CTAR2蛋白高效结合.硝酸纤维膜斑点印迹法证实阳性率达到100％.测序结果显示噬菌体上的短肽有共同序列:GLKHHSPGLLLY.结论 筛选出与CTAR2蛋白特异性结合的短肽序列GLKHHSPGLLLY,为研究LMP1致瘤机制和开发拮抗LMP1蛋白的小分子短肽类药物提供实验依据.     

从噬菌体随机环七肽库筛选可模拟C1qR的C1q结合肽

为获得能结合C1q并模拟C1q受体 (C1qR )配体结合位点的短肽 ,以C1q为钓饵蛋白筛选噬菌体环七肽库 ,采用C1q结合ELISA、U937细胞配体结合抑制试验、多聚IgG (AIgG )竞争抑制试验鉴定阳性克隆 ,再进行单链DNA测序和分析。结果经 3轮筛选后 ,随机挑选 2 3个噬菌体克隆进行ELISA鉴定 ,10个克隆与C1q有较强的结合 ;利用U937细胞配体结合抑制试验 ,得到了 7个阳性克隆 ;从其展示肽DNA测序结果推导氨基酸序列 ,获得 7个短肽序列 :QTPFQLW、NPFNWTS、SPFXLTS、FLTWLDP、FSTFLYP、GPMWWSY和NPFXLIL。     

Selection of the specific coalescent peptide of human CD59 by phage display techniques

To screen and identify the short peptides with specific binding activity to human CDS9 and to design the short-peptide clamp against tumor escape, the phage display peptide library containing 12 peptides was used to select the highly expressed specific coalescent peptide of human CD59 in CHO cells. Positive phage clones obtained after 5 rounds of biopanning and detected with ELISA were obtained , in which 8 of them with high binding activity to human CD59 were sequenced. The 3 sequences thus obtained showed high homology with each and certain homology with sequence with human CD2 (PubMed 339HGAAENSISPSS), and all contained primary structure HXAXXXXXXPXX, of which this sequence may be the mimic conformational epitope binding to human CD59. These results in the present study may be helpful to design the short-peptide clamp against the active sites of CD59 on tumor escape.     

噬菌体表达短肽模拟乙脑病毒糖蛋白的研究

为研究日本脑炎病毒 (JEV )E蛋白模拟肽 ,将抗JEVE蛋白的mAb 2H4淘筛噬菌体 15肽库。经夹心ELISA、竞争ELISA鉴定后 ,随机挑取 10个阳性克隆 ,测序并与JEVE蛋白同源比较。将阳性噬菌体免疫小鼠 ,检测血清中特异性抗体。ELISA结果显示筛选到的噬菌体能特异地与mAb 2H4结合 ,并且这种结合可被JEV天然抗原所竞争抑制。 10个阳性克隆的氨基酸序列相同 :—RQDPQWPYANSTIAR— ,同源分析得到的序列STXAR可能为mAb 2H4识别的模拟表位。阳性噬菌体表达的 15肽能够刺激小鼠产生特异性抗体。该噬菌体表达短肽模拟JEVE蛋白的部分抗原性。     

Effect of peptide seals specific to CD59 on the expression of apoptosis-related genes in HeLa cells.]

AIM: To study the effect of peptide seals specific to CD59 on the expression of apoptosis-related survivin, caspase-3 and bax in HeLa cells and investigate the mechanism of peptide seals specific to CD59 in inducing apoptosis of HeLa cells. METHODS: The peptide seals specific to CD59 were put into HeLa cells and HeLa cells with CD59-transfected gene, respectively. After 24 hours of interaction, the inhibitory ratio of cell proliferation was measured by MTT and the expression of survivin, caspase-3 and bax was detected by immunohistochemistry. RESULTS: The inhibitory ratio of HeLa cells with CD59-transfected gene+peptide seal group was higher than that of HeLa cells+peptide seal group. There was a significant difference in depressing the proliferation between two groups (P<0.01). Compared with HeLa cells+peptide seal group, the survivin expression of HeLa cells with CD59-transfected gene+peptide seal group was decreased (P<0.05) while caspase-3 expression was increased (P<0.05). There was no significant difference in the expression of bax in four groups. CONCLUSION: The peptide seal specific to CD59 can down-regulate the expression of survivin, activate caspase-3 and enhance the apoptosis of HeLa cells.     

从噬菌体15肽库中筛选乙脑病毒糖蛋白模拟肽

目的 用抗JEVE蛋白的mAb2H4筛选噬菌体15肽库,以研究JEVE蛋白模拟肽。方法 用生物素标记的mAb2H4,对噬菌体随机15肽库进行3轮筛选,经ELISA鉴定后,随机挑战取10个阳性噬菌体克隆测序,并与JEVE蛋白进行同源性比较,结果 筛选到的噬菌体能与mAb2H4特异地结合,并且这种结合可被天然JEV抗原所抑制,10个阳性噬菌体克隆的氨基酸序列相同,均为RQD-PQWPYANSTIAR,同源分析表明,在JEVE蛋白不同区域有两个同源性较高的序列：STXAR和WXXAXST,阳性噬菌体展示肽了能与抗天然JEV抗原的鼠血清产生特异性反应。结论 筛选的该噬菌体克隆展示肽可模拟JEVE蛋白的部分抗原性。     

Generation of microglia specific reagents from phage displayed peptide libraries

The present report concerns the generation of specific markers and the establishment of a selection procedure for microglia specific molecules from phage displayed peptide libraries. Negative selection against a mouse monocytic cell line (IC-21) and positive selection against primary mouse microglia was combined in the selection procedures using a mixture of two random peptide libraries displayed on phage. In a first set of experiments, one clone was selected that bound microglia and IC-21 cells to equal extent, and three clones that bound to unsorted primary microglia to substantially higher levels than to IC-21 cells. In the second series of experiments, microglia and IC-21 cells were mixed and CD45-positive microglia cells were collected using a FACS sorter. From the latter selection series, three clones were found that preferentially bound to microglia cells. The binding of one of the six selected microglia specific phage clones, clone V-1:19, was competed/inhibited in experiments using soluble synthetic peptides corresponding to the binding motif of the phage clone. The specific inhibition to microglia cells by this synthetic peptide was effective in the concentration range of 0.5-20 microM. The preferential binding of clone V-1:19 to microglia like cells was further demonstrated by staining a panel of cell lines and purified primary mouse microglia.     

用噬菌体肽库筛选IBDV单克隆抗体的模拟表位

目的:筛选法氏囊病毒(IBDV)单克隆抗体所针对的模拟抗原表位。方法:以纯化的3株IBDV单克隆抗体为靶分子用噬菌体12肽库筛选相应抗原模拟表位;应用间接和竞争ELISA鉴定所筛选的阳性样品;最后对与抗体高亲和结合的噬菌体进行测序分析。结果:经过四轮淘洗,随机挑取30个克隆经间接ELISA鉴定,发现其中22个克隆结合活性较高。进一步应用竞争ELISA,获得14个噬菌体克隆,其抑制率高达50%以上。对这些噬菌体进行DNA测序,并分析比对了IBDV相应序列,确定了3个抗原模拟表位。结论:通过噬菌体随机肽库成功筛选出3个IBDV模拟表位,为进一步研究IBDV抗原性质奠定了基础。     

Inhibition of CD40–CD154 costimulatory pathway by a cyclic peptide targeting CD154

Disruption of the CD40–CD154 interaction was found to be effective in the prevention and treatment of several immune-mediated diseases. The antibody-based strategy of inhibition was in humans limited by platelet activation leading to thrombotic effects. Other strategies different from antibody technology may be useful to create tools to interfere with CD40–CD154 pathway. In the present study, we selected and characterized from a phage display library, cyclic hepta-peptides specific for human CD154 through biopanning against plate-immobilized recombinant hCD154-muCD8. Nine phage clones were selected for the ability to bind CD154 expressed on the surface of J558L cells transfected with human CD154. From the nine selected phage clones, we obtained seven different amino acidic sequences, and the corresponding hepta-peptides rendered cyclic by two cysteines were synthesized. All the peptides specifically bound CD154 expressed on J558L. However, only the peptide 4.10 (CLPTRHMAC) was found to recognize the active binding site of CD154, as it competed with the blocking anti-CD154 antibody. When changes in the amino acid composition were introduced in the sequence of 4.10 peptide, the binding to CD154 was abrogated, suggesting that the amino acid sequence was critical for its specificity. This peptide was found to inhibit the CD40–CD154 interaction, preventing CD40-dependent activation of B lymphocytes in vitro as it was able, as the blocking anti-human CD154 mAb, to prevent the expression of CD80 and CD86 costimulatory molecules and switching of Ig isotype induced by CD154. Moreover, the peptide 4.10 inhibited the in vitro endothelial cell motility and organization into capillary-like structures, and the in vivo angiogenesis of human umbilical cord-derived endothelial cells implanted in Matrigel in severe combined immunodeficiency mice. In vitro studies on platelet activation demonstrated that the 4.10 peptide, at variance of the anti-CD154 mAb, was unable to prime human platelet activation and aggregation. In conclusion, we identify a cyclic hepta-peptide able to displace the binding of human CD154 to CD40 expressed on cell surface and to abrogate some biological effects related to the CD40 stimulation, such as B cell activation and endothelial triggered angiogenesis.